Trial Profile

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer [SUBSTUDY OF 700216591]

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary)
Indications Carcinoma; Early breast cancer
Focus Therapeutic Use
Acronyms ADAPT; ADAPT HR+/HER2-

Most Recent Events

08 Apr 2025 Status changed from active, no longer recruiting to completed.
12 Nov 2024 Planned End Date changed from 1 Oct 2024 to 1 Jan 2025.
24 Oct 2023 Results (n=4491) assessing the impact of recurrence score, clinical-pathological factors, gene mutations and histology in early HR+/HER2- breast cancer, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com